S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
S&P 500   4,298.86 (+0.11%)
DOW   33,876.78 (+0.13%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:XOMA

XOMA (XOMA) Stock Forecast, Price & News

$17.21
-0.53 (-2.99%)
(As of 06/9/2023 ET)
Compare
Today's Range
$17.00
$17.75
50-Day Range
$17.00
$21.58
52-Week Range
$15.68
$32.08
Volume
33,758 shs
Average Volume
32,551 shs
Market Capitalization
$197.23 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$69.00

XOMA MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
300.9% Upside
$69.00 Price Target
Short Interest
Bearish
4.98% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.22
Upright™ Environmental Score
News Sentiment
0.78mentions of XOMA in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$157,134 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.44) to ($0.45) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.09 out of 5 stars

Medical Sector

370th out of 987 stocks

Pharmaceutical Preparations Industry

171st out of 477 stocks


XOMA stock logo

About XOMA (NASDAQ:XOMA) Stock

XOMA Corp. engages in the discovery and development of therapeutics derived from platform of antibody technologies. Its products includes X358, X213, X129, and gevokizumab. The company was founded by Patrick J. Scannon in 1981 and is headquartered in Emeryville, CA.

Receive XOMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for XOMA and its competitors with MarketBeat's FREE daily newsletter.

XOMA Stock News Headlines

Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
XOMA Co. (NASDAQ:XOMA) CEO Owen Hughes Purchases 968 Shares
XOMAP XOMA Corporation 8.625% CUM PERP PFD SER A
Why did Biden repeal Trump's Executive Order?!
" Why did Biden repeal Trump's Executive Order?! Within 10 days of taking office, President Trump signed "Executive Order 13771" in an effort to win the battle for what 60 minutes said could be "the most consequential discovery in biomedicine this century." So why did Biden repeal this? Click here to learn more >>> "
XOMA: Q1 Earnings Insights
See More Headlines

XOMA Price History

XOMA Company Calendar

Last Earnings
11/04/2021
Today
6/09/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:XOMA
CUSIP
98419J10
Employees
12
Year Founded
1981

Price Target and Rating

Average Stock Price Forecast
$69.00
High Stock Price Forecast
$69.00
Low Stock Price Forecast
$69.00
Forecasted Upside/Downside
+292.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-17,100,000.00
Net Margins
-774.65%
Pretax Margin
-734.35%

Debt

Sales & Book Value

Annual Sales
$6.03 million
Book Value
$10.83 per share

Miscellaneous

Free Float
10,865,000
Market Cap
$201.58 million
Optionable
Not Optionable
Beta
0.85

Social Links


Key Executives

  • Owen Patrick Hughes
    Chairman & Chief Executive Officer
  • Thomas Burns
    Chief Financial Officer & Senior VP-Finance
  • Bradley J. Sitko
    Chief Investment Officer
  • Juliane Snowden
    Investor Relations Contact













XOMA Stock - Frequently Asked Questions

Should I buy or sell XOMA stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for XOMA in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" XOMA shares.
View XOMA analyst ratings
or view top-rated stocks.

What is XOMA's stock price forecast for 2023?

1 brokerages have issued 12 month target prices for XOMA's shares. Their XOMA share price forecasts range from $69.00 to $69.00. On average, they predict the company's share price to reach $69.00 in the next year. This suggests a possible upside of 292.3% from the stock's current price.
View analysts price targets for XOMA
or view top-rated stocks among Wall Street analysts.

How have XOMA shares performed in 2023?

XOMA's stock was trading at $18.40 on January 1st, 2023. Since then, XOMA stock has decreased by 4.4% and is now trading at $17.59.
View the best growth stocks for 2023 here
.

When is XOMA's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our XOMA earnings forecast
.

How were XOMA's earnings last quarter?

XOMA Co. (NASDAQ:XOMA) announced its earnings results on Thursday, November, 4th. The biotechnology company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.31. The biotechnology company earned $0.94 million during the quarter, compared to analyst estimates of $6.36 million. XOMA had a negative trailing twelve-month return on equity of 20.65% and a negative net margin of 774.65%.

What is John Varian's approval rating as XOMA's CEO?

11 employees have rated XOMA Chief Executive Officer John Varian on Glassdoor.com. John Varian has an approval rating of 73% among the company's employees.

What other stocks do shareholders of XOMA own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XOMA investors own include Cytokinetics (CYTK), Alnylam Pharmaceuticals (ALNY), Ascent Solar Technologies (ASTI), CTI BioPharma (CTIC), OPKO Health (OPK), Uranium Energy (UEC), Gilead Sciences (GILD), NXP Semiconductors (NXPI) and Ekso Bionics (EKSO).

What is XOMA's stock symbol?

XOMA trades on the NASDAQ under the ticker symbol "XOMA."

Who are XOMA's major shareholders?

XOMA's stock is owned by many different institutional and retail investors. Top institutional investors include BVF Inc. IL (31.71%), FMR LLC (10.77%), Stonepine Capital Management LLC (2.78%), Acuitas Investments LLC (0.76%), Geode Capital Management LLC (0.71%) and Susquehanna International Group LLP (0.44%). Insiders that own company stock include Bradley Sitko, Bvf Partners L P/Il, James R Neal, James R Neal, Matthew D Perry, Owen Hughes, Thomas M Burns and Value Fund L P Biotechnology.
View institutional ownership trends
.

How do I buy shares of XOMA?

Shares of XOMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is XOMA's stock price today?

One share of XOMA stock can currently be purchased for approximately $17.59.

How much money does XOMA make?

XOMA (NASDAQ:XOMA) has a market capitalization of $201.58 million and generates $6.03 million in revenue each year. The biotechnology company earns $-17,100,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis.

How can I contact XOMA?

XOMA's mailing address is 2200 POWELL STREET SUITE 310, EMERYVILLE CA, 94608. The official website for the company is www.xoma.com. The biotechnology company can be reached via phone at (510) 204-7200, via email at jsnowden@oratoriumgroup.com, or via fax at 510-649-7571.

This page (NASDAQ:XOMA) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -